Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma

Su, Min-Cheng; Lien, Han‐Chung; Jeng, Yung‐Ming

doi:10.1016/j.canlet.2004.10.010

Cited by 49 publications

(37 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the high frequency of EGFR expression in HCC, activation mutations in the EGFR kinase domain are not detected (69). These results indicate that a different mechanism for the regulation of EGFR function may operate during HCC pathogenesis and progression.…”

Section: Discussionmentioning

confidence: 80%

Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity

Liu

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: GALNT, the initial enzyme in mucin-type O-glycosylation, plays critical roles in cancer etiology. Results: GALNT10-induced cellular proliferation was associated with EGFR activation mediated by down-regulation of miR-122 in HBV-associated HCC. Conclusion: A regulatory pathway of Hnf4␣/miR-122/GALNT10/EGFR may represent a possible mechanism underlying HBV-associated hepatocarcinogenesis. Significance: This finding provides a novel role for O-glycosylation in HCC pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 80%

Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity

Liu

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Moreover, Barber et al (38) demonstrated only one (0.3%) mutation in 293 colorectal cancers and 59 glioblastomas (exons [17][18][19][20][21][22][23][24]. In an Asian study, Su et al (39) examined exons 18-21 in 89 hepatocellular carcinomas, but detected no EGFR mutation. Lee et al (40) demonstrated the same mutation (an in-frame deletion mutation in exon 19, E746_A750del) in 3 (7.3%) of 41 head and neck carcinomas.…”

Section: Discussionmentioning

confidence: 99%

Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines

Kimura¹,

Maesawa²,

Ikeda³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors including gastrointestinal tract tumors. Gefitinib is a selective inhibitor of EGFR tyrosine kinase, and blocks several signal transduction pathways including those involved in tumor cell proliferation, angiogenesis and metastasis. Recent mutational and biological studies have suggested that mutations in the tyrosine kinase domain of the EGFR gene are well correlated with the response to gefitinib, and that these mutations are frequently observed in non-small cell lung cancers affecting women, East Asians and nonsmokers. This led us to speculate that EGFR gene mutations may occur frequently in gastrointestinal tract carcinomas (GITCs) because over-expression is observed in these tumor types. To investigate EGFR mutations in GICTs, we studied 11 esophageal, 6 gastric, and 12 colorectal cancer cell lines. We found a missense mutation in a gastric cancer cell line, and 10 single nucleotide polymorphisms. The occurrence of rare mutations in the tyrosine kinase domain of the EGFR gene suggests that gefitinib is unlikely to be reliable as single-drug therapy for GITCs.

show abstract

“…However, in a recent report that examined 89 human HCC samples no such mutations were found, suggesting that human liver tumors are unlikely to show a good response to gefitinib (Su et al, 2005). Additionally, enhanced expression of EGFR ligands can also induce tumor cell resistance to EGFR inhibitors.…”

Section: Biological Therapymentioning

confidence: 97%

New therapies for hepatocellular carcinoma

et al. 2006

View full text Add to dashboard Cite

Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma

Cited by 49 publications

References 24 publications

Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity

Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity

Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines

New therapies for hepatocellular carcinoma

Contact Info

Product

Resources

About